Clearbridge Biomedics

Clearbridge BioMedics is an innovative company focused on cancer research and diagnostic technologies. It has a real-time liquid biopsy product based on a label-free CTC enrichment technology jointly developed by MIT and the National University of Singapore. Its core product, the ClearCell® FX1 system, utilizes an innovative microfluidic technology based on Dean flow fractionation, enabling highly automated and efficient label-free separation of CTCs with intact morphology and preserved cell viability from patient blood.